This trial is studying the safety and efficacy of PLG0206 in treating patients with periprosthetic joint infections (PJI) after total knee arthroplasty (TKA) using the DAIR surgical procedure.
1 Primary · 0 Secondary · Reporting Duration: approximately 1 year
Experimental Treatment
14 Total Participants · 2 Treatment Groups
Primary Treatment: PLG0206 · No Placebo Group · Phase 1
Age 18 - 79 · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: